Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
Imagion Bio CEO, Robert Proulx, presents company information to investors at the 2022 Switzer Small & Micro Cap Conference in September. Video Transcript: Thank you,
https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid nanoparticles often involves multiple steps.
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here. Other
Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my pleasure to welcome
As a sponsor of the 2021 Annual VBIC Network Meeting, Imagion Biosystems’ President and CEO, Bob Proulx, gave a presentation on magnetic nanoparticles as imaging
Come along to Switzer Small & Micro Cap Investor Day Switzer Financial Group is pleased to bring you the Switzer Small & Micro Cap Investor
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
